Skip to main content

Advertisement

SpringerLink
Log in

Progressive Multifocal Leukoencephalopathy as a Complication of Disease-modifying Treatment of Multiple Sclerosis

  • Published:
Human Physiology Aims and scope Submit manuscript

Abstract

The review provides modern understanding of the pathogenesis of progressive multifocal leukoencephalopathy (PML), a severe and potentially fatal form of multiple-lesion disorder of the brain white matter. Information about the frequency of its development in patients with disease-modifying treatment of multiple sclerosis is analyzed. The algorithms of optimization of PML risks in this category of patients with multiple sclerosis are described in detail. Summarized are the data on most significant PML biomarkers, the search for which is currently under way in many centers across the world. The first case of PML in Russia is briefly described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Zavalishin, I.A. and Zakharova, M.N., Multiple sclerosis: results and perspectives of the study, Zh. Nevropatol. Psikhiatr. im. S.S. Korsakova, 1982, vol. 82, no. 2, pp. 161–167.

    CAS  PubMed  Google Scholar 

  2. Zavalishin, I.A., Zakharova, M.N., Zhuchenko, T.D., and Peresedova, A.V., Etiology and pathogenesis of multiple sclerosis, in Rasseyannyi skleros. Izbrannye voprosy teorii i praktiki (Multiple Sclerosis: Selected Issues of Theory and Practice), Zavalishin, I.A. and Golovkin, V.I., Eds., Moscow: Issled. Tsentr Nevrol., Ross. Akad. Med. Nauk, 2000, pp. 537–579.

  3. Bisaga, G.N., Kovalenko, A.V., Isayeva, G.E., et al., The use of mesenchymal stem cells in optic atrophy in patients with multiple sclerosis: a pilot study, Ann. Klin. Eksp. Nevrol., 2017, vol. 11, no. 2, pp. 26–31.

    Google Scholar 

  4. Ryabtseva, M.S., Negudova, N.P., Batuashvili, T.A., and Simutenko, L.V., Experimental evaluation of bioequivalence of original and reproduced peptide preparations in multiple sclerosis, Ann. Klin. Eksp. Nevrol., 2018, vol. 12, no. 2, pp. 39–44.

    Google Scholar 

  5. Votintseva, M.V., Petrov, A.M., and Stolyarov, I.D., Drugs based on monoclonal antibodies: The present and the future in the treatment of multiple sclerosis (based on the materials of the 32nd Congress of the European Committee for the Treatment and Research of Multiple Sclerosis–ECTRIMS), Ann. Klin. Eksp. Nevrol., 2017, vol. 11, no. 2, pp. 83–88.

  6. Zakharova, M.N., Logunov, D.Yu., Kochergin, I.A., and Bakulin, I.S., Endogenous retroviruses: from basic research to etiotropic therapy for multiple sclerosis, Ann. Klin. Eksp. Nevrol., 2015, vol. 9, no. 4, pp. 49–53.

    Google Scholar 

  7. Zakharova, M.N., Lipid myelin, in Rasseyannyi skleros. Izbrannye voprosy teorii i praktiki (Multiple Sclerosis: Selected Issues of Theory and Practice), Zavalishin, I.A. and Golovkin, V.I., Eds., Moscow: Issled. Tsentr Nevrol., Ross. Akad. Med. Nauk, 2000, pp. 69–96.

  8. Boiko, A.N., Lashch, N.Yu., Sharanova, S.N., et al., A comparative Placebo-controlled clinical trial of the efficacy and safety of glatiramer acetate 20 mg in patients with remitting multiple sclerosis: first-year study results, Neurosci. Behav. Physiol., 2018, vol. 48, no. 3, pp. 351–357.

    Article  CAS  Google Scholar 

  9. Korzhova, Yu.E., Vorob’eva, A.A., Ivanova, M.V., et al., A comparison of the efficacy of natalizumab or fingolimod as second-line drugs in patients with multiple sclerosis, Med. Mente. Lechim Umom, 2016, no. 1, pp. 63–66.

  10. Hallervorden, J., Eigennartige and nicht rubriziebare prozesse, in Handbuch der Geiteskranheiten, Die Anatomie der Phychosen, Bumke, O., Ed., Berlin: Springer-Verlag, 1930, vol. 2, pp. 1063–1107.

    Google Scholar 

  11. Astrom, K.E., Mancell, E.L., and Richardson, E.P.J., Progressive multifocal encephalopathy: A hitharto unrecognized complication of chronic lymphocytic leukemia and lymphoma, Brain, 1958, vol. 81, pp. 99–111.

    Article  Google Scholar 

  12. ZuRhein, G.M. and Chou, S.M., Particles resembling papova-virus in human cerebral demyelinating disease, Science, 1965, vol. 148, pp. 1477–1479.

    Article  CAS  Google Scholar 

  13. ZuRhein, G.M., Association of papova-virions with a human demyelination disease (progressive multifocal leukoencephalopathy), Prog. Med. Virol., 1969, vol. 11, pp. 185–248.

    CAS  Google Scholar 

  14. Padgett, B.L., Walker, D.L., ZuRhein, G.M., et al., Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy, Lancet, 1971, vol. 1, pp. 1257–1260.

    Article  CAS  Google Scholar 

  15. Frisque, R.J., Bream, G.L., and Cannella, M.T., Human polyomavirus JC virus genome, J. Virol., 1984, vol. 51, pp. 458–469.

    Article  CAS  Google Scholar 

  16. Gardner, S.D., Feild, A.M., Colleman, D.V., and Hulme, B., New human papovavirus (BK) isolated from urine after renal transplantation, Lancet, 1971, vol. 1, pp. 1253–1257.

    Article  CAS  Google Scholar 

  17. Knowles, W.A., Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV), Adv. Exp. Med. Biol., 2006, vol. 577, pp. 19–45.https://doi.org/10.1007/0-387-32957-9_2

    Article  CAS  PubMed  Google Scholar 

  18. Reid, C.E., Li, H., Sur, G., et al., Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients, J. Infect. Dis., 2011, vol. 204, pp. 237–244.https://doi.org/10.1093/infdis/jir256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Warnke, C., Adams, O., and Kieseier, B., Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis, J.A.M.A. Neurol., 2014, vol. 71, p. 1192. https://doi.org/10.1001/jamaneurol.2014.1858

    Article  Google Scholar 

  20. Zakharova, M.N., Progressive multifocal leukoencephalopathy (literature review), Zh. Nevropatol. Psikhiatr. im. S.S. Korsakova, 2012, vol. 112, no. 9-2, pp. 29–33.

  21. Physician information and management guidelines for multiple sclerosis patients on TYSABRI therapy, European Medicines Agency, 2016. https://www.medicines.org.uk/emc/rmm/1199/Document.

  22. Carrillo-Infante, C., Richman, S., Yu, B., et al., Functional and survival outcomes of asymptomatic progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients: 2015 update, ECTRIMS Online Library 2016, 2016, no. EP1528.

  23. Power, C., Gladden, J.G., Halliday, W., et al., AIDS- and non-AIDS-related PML association with distinct p53 polymorphism, Neurology, 2000, vol. 54, pp. 743–746.

    Article  CAS  Google Scholar 

  24. Antinori, A., Ammassari, A., Giancola, M.L., et al., Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era, J. Neurovirol., 2001, vol. 7, pp. 323–328. https://doi.org/10.1080/13550280152537184

    Article  CAS  PubMed  Google Scholar 

  25. García-Suárez, J., de Miguel, D., Krsnik, I., et al., Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies, Am. J. Hematol., 2005, vol. 80, pp. 271–281. https://doi.org/10.1002/ajh.20492

    Article  CAS  PubMed  Google Scholar 

  26. Clavel, G., Moulignier, A., and Semerano, L., Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments, Joint Bone Spine, 2017, vol. 84, pp. 671–675. https://doi.org/10.1016/j.jbspin.2017.03.002

    Article  PubMed  Google Scholar 

  27. Molloy, E.S. and Calabrese, L.H., Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases, Arthritis Rheumatol., 2009, vol. 60, pp. 3761–3765. https://doi.org/10.1002/art.24966

    Article  Google Scholar 

  28. Asztely, F., Gilland, E., Wattjes, M.P., and Lycke, J., Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis, J. Neurol. Sci., 2015, vol. 353, pp. 155–157. https://doi.org/10.1016/j.jns.2015.04.010

    Article  CAS  PubMed  Google Scholar 

  29. Carson, K.R., Evens, A.M., Richey, E.A., et al., Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports Project, Blood, 2009, vol. 113, pp. 4834–4840. https://doi.org/10.1182/blood-2008-10-186999

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ho, P.R., Koendgen, H., Campbell, N., et al., Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies, Lancet Neurol., 2017, vol. 16, pp. 925–933. https://doi.org/10.1016/S1474-4422(17)30282-X

    Article  CAS  PubMed  Google Scholar 

  31. Mills, E.A. and Mao-Draayer, Y., Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: a bird’s eye view, Front. Immunol., 2018, vol. 9, p. 138. https://doi.org/10.3389/fimmu.2018.00138

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Klinicheskiye rekomendatsii. Rasseyannyy skleroz (Clinical Recommendations. Multiple Sclerosis), Gusev, E.I. and Gekht, A.B., Eds., Moscow: Minist. Zdravookhr. Ross. Fed., 2018.

    Google Scholar 

  33. Motte, J., Kneiphof, J., Straßburger-Krogias, K., et al., Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML, J. Neurol., 2018, vol. 265, pp. 1880–1882. https://doi.org/10.1007/s00415-018-8931-7

    Article  PubMed  Google Scholar 

  34. Bloomgren, G., Richman, S., Hotermans, C., et al., Risk of natalizumab-associated progressive multifocal leukoencephalopathy, N. Engl. J. Med., 2012, vol. 366, pp. 1870–1880. https://doi.org/10.1056/NEJMoa1107829

    Article  CAS  PubMed  Google Scholar 

  35. Carotenuto, A., Scalia, G., Ausiello, F., et al., CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients, J. Neuroimmunol., 2017, vol. 309, pp. 47–50. https://doi.org/10.1016/j.jneuroim.2017.05.006

    Article  CAS  PubMed  Google Scholar 

  36. Iannetta, M., Zingaropoli, M.A., Bellizzi, A., et al., Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation, PLoS One, 2016, vol. 11, p. e0160277. https://doi.org/10.1371/journal.pone.0160277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Jilek, S., Mathias, A., Canales, M., et al., Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients, Mult. Scler. J., 2014, vol. 20, pp. 837–842. https://doi.org/10.1177/1352458513513208

    Article  CAS  Google Scholar 

  38. Savage, N.D., Harris, S.H., Rossi, A.G., et al., Inhibition of TCR-mediated shedding of L-selectin (CD62L) on human and mouse CD4+ T cells by metalloproteinase inhibition: analysis of the regulation of Th1/Th2 function, Eur. J. Immunol., 2002, vol. 32, pp. 2905–2914. https://doi.org/10.1002/15214141(2002010)32:10<2905::AID-IMMU2905>3.0.CO;2-6

    Article  CAS  PubMed  Google Scholar 

  39. Basnyat, P., Hagman, S., Kolasa, M., et al., Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients, Mult. Scler. Relat. Disord., 2015, vol. 4, pp. 334–338. https://doi.org/10.1016/j.msard.2015.06.008

    Article  PubMed  Google Scholar 

  40. Schwab, N., Schneider-Hohendorf, T., Posevitz, V., et al., L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients, Neurology, 2013, vol. 81, pp. 865–871. https://doi.org/10.1212/WNL.0b013e3182a351fb

    Article  CAS  PubMed  Google Scholar 

  41. Lieberman, L.A., Zeng, W., Singh, C., et al., CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients, Neurology, 2016, vol. 86, pp. 375–381. https://doi.org/10.1212/WNL.0000000000002314

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Zakharova, M.N., Lysogorskaia, E.V., Trushniko-va, T.N., and Zhelnin, A.V., The case of development of progressive multifocal leukoencephalopathy in a pa-tient with multiple sclerosis on the background of taking natalizumab, Zh. Nevropatol. Psikhiatr. im. S.S. Korsakova, 2018, no. 8-2, pp. 106–108.

Download references

Author information

Authors and Affiliations

  1. Research Center of Neurology, Moscow, Russia

    M. N. Zakharova, E. V. Lysogorskaia, M. V. Ivanova, I. A. Kochergin & Y. E. Korzhova

Authors
  1. M. N. Zakharova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. V. Lysogorskaia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. V. Ivanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. A. Kochergin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. E. Korzhova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. V. Lysogorskaia.

Ethics declarations

Conflict of interests. The authors declare that there is no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zakharova, M.N., Lysogorskaia, E.V., Ivanova, M.V. et al. Progressive Multifocal Leukoencephalopathy as a Complication of Disease-modifying Treatment of Multiple Sclerosis. Hum Physiol 45, 863–868 (2019). https://doi.org/10.1134/S0362119719080097

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0362119719080097

Keywords:

Search

Navigation